What's in Melanoma and Skin Cancer Trials Limited's pipeline?

Melanoma and Skin Cancer Trials Limited has 1 drugs in our index: 0 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Melanoma and Skin Cancer Trials Limited's portfolio?

Top competitors by shared drug class: Children's Hospital of Fudan University, Chong Kun Dang Pharmaceutical, Exelixis, GlaxoSmithKline, Grupo Espanol de Tumores Neuroendocrinos.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/melanoma-and-skin-cancer-trials-limited.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Melanoma and Skin Cancer Trials Limited — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Melanoma and Skin Cancer Trials Limited pipeline: 0 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Sirolimus Topical Cream	Sirolimus Topical Cream	phase 3	mTOR inhibitor	mTOR (mammalian target of rapamycin)	Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Children's Hospital of Fudan University · 1 shared drug class
Chong Kun Dang Pharmaceutical · 1 shared drug class
Exelixis · 1 shared drug class
GlaxoSmithKline · 1 shared drug class
Grupo Espanol de Tumores Neuroendocrinos · 1 shared drug class
H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
Hannover Medical School · 1 shared drug class
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Melanoma and Skin Cancer Trials Limited:

Cite this brief

Drug Landscape (2026). Melanoma and Skin Cancer Trials Limited — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/melanoma-and-skin-cancer-trials-limited. Accessed 2026-05-18.